bis-PEG2-endo-BCN is a bifunctional ADC linker with two endo-BCN groups connected via PEG2 spacer, facilitating dual strain-promoted click conjugations in antibody-drug conjugate synthesis.
Structure of 1476737-97-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Bis-PEG2-endo-BCN, a versatile bifunctional linker, finds extensive utility in bioconjugation and drug delivery realms. Here are four key applications of Bis-PEG2-endo-BCN presented with high perplexity and burstiness:
1. Targeted Drug Delivery: Bis-PEG2-endo-BCN offers a sophisticated means of directing therapeutic agents to precise cells or tissues by binding to biomolecules like antibodies. This targeted strategy minimizes off-target effects, amplifying the therapeutic potency of the drug. Its significance shines in cancer therapy, where accurate delivery to tumor cells holds paramount importance.
2. Diagnostic Imaging: Leveraging Bis-PEG2-endo-BCN, researchers can conjugate imaging agents to targeting ligands, enriching diagnostic imaging practices. This application elevates the contrast and specificity of imaging modalities such as MRI or PET scans, enabling superior visualization and early detection of diseases like cancer and cardiovascular disorders.
3. Protein-Protein Interaction Studies: Bis-PEG2-endo-BCN plays a pivotal role in probing protein-protein interactions, uniting proteins with reporter molecules. This facilitates real-time tracking of complex formation and dissociation, shedding light on protein function and signaling pathways. Unraveling these intricate interactions is indispensable for drug discovery and biochemical investigations.
4. Development of Bioconjugates: Widely embraced in bioconjugate synthesis, Bis-PEG2-endo-BCN fuels the creation of innovative constructs like antibody-drug conjugates (ADCs) and enzyme-prodrug conjugates. By tethering bioactive compounds to carriers or functional molecules, researchers craft novel therapeutics endowed with heightened stability and specificity.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00907 | Bis-PEG8-acid | 1246189-43-4 | |
BADC-00913 | Bis-PEG9-acid | 1268488-70-5 | |
BADC-00379 | Bis-PEG4-NHS ester | 1314378-11-4 | |
BADC-00380 | Bis-PEG3-NHS Ester | 1314378-16-9 | |
BADC-00922 | Bis-PEG2-PFP ester | 1314378-18-1 | |
BADC-00924 | Bis-PEG7-NHS ester | 1334170-02-3 | |
BADC-00960 | Bis-PEG6-NHS ester | 1526718-98-8 | |
BADC-01006 | Bis-PEG1-PFP ester | 1807539-02-1 | |
BADC-01036 | Bis-(PEG6-acid)-SS | 2055014-97-4 | |
BADC-01080 | Bis-PEG17-NHS ester | 2221948-93-0 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.